BlackRock’s Galmed Pharmaceuticals GLMD Stock Holding History

BlackRock’s Portfolio GLMD Stock Details GLMD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-51	Closed	-$14K	–	5895
2022 Q1	$14K	Hold	51	–	–	﹤0.01%	5610
2021 Q4	$17K	Hold	51	–	–	﹤0.01%	5558
2021 Q3	$25K	Hold	51	–	–	﹤0.01%	5373
2021 Q2	$28K	Hold	51	–	–	﹤0.01%	5251
2021 Q1	$31K	Buy	51 +9	+21%	+$6.23K	﹤0.01%	4975
2020 Q4	$24K	Buy	42 +9	+27%	+$5.62K	﹤0.01%	4759
2020 Q3	$21K	Hold	33	–	–	﹤0.01%	4710
2020 Q2	$28K	Buy	+33	New	+$27.8K	﹤0.01%	4648
2019 Q1	–	Sell	-26	Closed	-$33K	–	4967
2018 Q4	$33K	Buy	+26	New	+$45.4K	﹤0.01%	4529

Other funds holding GLMD

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

RJA

Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return

RJFSA

Raymond James Financial Services Advisors St. Petersburg, Florida $75.1B AUM 31.89% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

WWM

Western Wealth Management Golden, Colorado $2.63B AUM 21.3% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Cambridge Investment Research Advisors Fairfield, Iowa $38.8B AUM 21.88% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

BlackRock's GLMD Position: Q2 2022 in Review

BlackRock sold out of Galmed Pharmaceuticals (GLMD) in Q2 2022, closing a stake of 51 shares — an estimated $14K sold.

BlackRock first reported a position in GLMD in Q4 2018 and held it in 9 quarters. The position peaked at $33K in Q4 2018. 22 funds tracked by Wall St. Rank hold GLMD as of Q2 2022.

BlackRock reported no remaining Galmed Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
BlackRock sold 51 Galmed Pharmaceuticals shares in Q2 2022, an estimated $14K.
BlackRock first reported a position in Galmed Pharmaceuticals in Q4 2018 and held it in 9 quarters.
BlackRock's Galmed Pharmaceuticals position peaked at $33K in Q4 2018.
22 funds tracked by Wall St. Rank held Galmed Pharmaceuticals as of Q2 2022.

Based on BlackRock's 13F filing for Q2 2022, filed 12 Aug 2022.